MABC534MI
MilliporeSigma™ Mouse anti-TPM3, Clone: TC22-4,
Manufacturer: MilliporeSigma™
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | MABC534MI-Each-of-1 | In Stock | ₹ 40,228.00 |
MABC534MI - Each of 1
In Stock
Quantity
1
Base Price: ₹ 40,228.00
GST (18%): ₹ 7,241.04
Total Price: ₹ 47,469.04
Antigen
TPM3
Classification
Monoclonal
Formulation
Purified mouse monoclonal IgG1κ antibody in buffer containing 0.1M Tris-Glycine (pH 7.4), 150mM NaCl with 0.05% sodium azide.
Gene Symbols
TPM3
Immunogen
Recombinant human TC22 and boosts with TC22-specific C-terminal peptide.
Quantity
100 μg
Research Discipline
Apoptosis, Cancer
Gene ID (Entrez)
NP_000357
Content And Storage
Stable for one year at 2°C to 8°C from date of receipt.
Isotype
IgG1 κ
Applications
ELISA, Flow Cytometry, Immunohistochemistry, Western Blot
Clone
TC22-4
Gene Accession No.
P06753-4
Host Species
Mouse
Purification Method
Protein G Purified
Regulatory Status
RUO
Primary or Secondary
Primary
Target Species
Human
Form
Purified
Related Products
Description
- Specifically detects TPM3 clone: TC22-4 in Human samples, and it is validated for ELISA, Flow Cytometry, Immunohistochemistry, Western Blotting Tropomyosins are dimmers of coiled-coil proteins that provide stability to actin filaments and regulate access of other actin-binding proteins
- The human TPM3 gene (Gene ID 7170; also known as TM3, TM5, TRK, CFTD, NEM1, TM-5, TM30, CAPM1, TM30nm, TPMsk3, hscp30, HEL-189, HEL-S-82p, OK/SW-cl.5) encodes seven tropomyosin alpha-3 chain isoforms (UniProt P06753; also known as Tropomyosin-3) as a result of alternative splicing
- Spliced variants 1, 2, 4, and 5 are also known as the skeletal muscle, TM30nm, TC22, and hTM5 isoform, respectively
- The TC22 and the hTM5 variants are identical in sequence other than the 25 amino acids at their C-terminal end
- TC22 is expressed in 100% of colorectal carcinomas, but is not expressed in normal colon epithelial cells
- The anticarcinogenic potency of sulfasalazine (SASP) and its active metabolite 5-aminosalicylate (5-ASA, mesalamine) in protecting ulcerative colitis (UC) patients from developing colorectal cancer is directly linked to their efficacy in reducing cellular expression of TC22
- Likewise, siRNA-mediated TC22 downregulation is shown to significantly alter several critical carcinogenic pathways in the human colon adenocarcinoma LS180 cells.